

**JEREMIAH B. FRUEAUF**  
ATTORNEY  
(202) 772-8506  
JFRUEAUF@SKGF.COM



February 4, 2011

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Confirmation No. 2306**  
**Art Unit 1646**  
**Attn: Mail Stop Amendment**

Re: U.S. Utility Patent Application  
Application No. 10/587,714; 371(c) Date: June 4, 2007  
For: **Treatment of Conditions Involving Dopaminergic Neuronal  
Degeneration Using Nogo Receptor Antagonists**  
Inventors: RELTON *et al.*  
Our Ref: 2681.0450001/EJH/JBF

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Fifth Supplemental Information Disclosure Statement;
2. Form PTO/SB/08a (1 sheet) listing 1 document (FP16);
3. Form PTO/SB/08b (1 sheet) listing 4 documents (NPL44-NPL47); and
4. Copies of cited documents (FP16 and NPL44-NPL47).

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jeremiah B. Frueauf  
Attorney for Applicants  
Registration No. 66,638

JBf/amb  
Enclosures

1317038\_1.doc